小林和史

研究者氏名	小林和史
	コバヤシカズフミ
URL
所属	千葉大学
部署	大学院医学研究院　消化器内科学
職名
学位	医学博士(千葉大学)
科研費研究者番号	40836615
J-Global ID	202101015962864350

論文

<3 456 7 >

Changes in therapeutic options for hepatocellular carcinoma in Asia.

Sadahisa Ogasawara Keisuke Koroki Hiroaki Kanzaki Kazufumi Kobayashi Soichiro Kiyono Masato Nakamura Naoya Kanogawa Tomoko Saito Takayuki Kondo Ryo Nakagawa Shingo Nakamoto Ryosuke Muroyama Tetsuhiro Chiba Naoya Kato

Liver international : official journal of the International Association for the Study of the Liver 42(9) 2055-2066 2022年8月

The incidence rate of hepatocellular carcinoma (HCC) is expected to increase, with most cases occurring in Asia. In some parts of Asia, the occurrence of HCC developing from metabolic-related liver disease has markedly increased in recent years, w...

Management of Systemic Therapies and Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma Based on Sarcopenia Assessment.

Takahiro Yamasaki Issei Saeki Yurika Yamauchi Toshihiko Matsumoto Yutaka Suehiro Tomokazu Kawaoka Shinsuke Uchikawa Akira Hiramatsu Hiroshi Aikata Kazufumi Kobayashi Takayuki Kondo Sadahisa Ogasawara Tetsuhiro Chiba Taro Takami Kazuaki Chayama Naoya Kato Isao Sakaida

Liver cancer 11(4) 329-340 2022年7月

Background: Sarcopenia, defined as the loss of skeletal muscle mass (MM), physical performance, and strength, has been associated with poor clinical outcomes in hepatocellular carcinoma (HCC) patients treated with several therapies. As systemic th...

Liver biopsy technique in the era of genomic cancer therapies: a single-center retrospective analysis.

Yusuke Ozeki Naoya Kanogawa Sadahisa Ogasawara Keita Ogawa Takamasa Ishino Miyuki Nakagawa Kisako Fujiwara Hidemi Unozawa Terunao Iwanaga Takafumi Sakuma Naoto Fujita Ryuta Kojima Hiroaki Kanzaki Keisuke Koroki Kazufumi Kobayashi Masato Nakamura Soichiro Kiyono Takayuki Kondo Tomoko Saito Ryo Nakagawa Eiichiro Suzuki Yoshihiko Ooka Shingo Nakamoto Ryosuke Muroyama Akinobu Tawada Tetsuhiro Chiba Makoto Arai Jun Kato Jun-Ichiro Ikeda Yuichi Takiguchi Naoya Kato

International journal of clinical oncology 27(9) 1459-1466 2022年6月

BACKGROUND: With the evolution of personalized medicine in the field of oncology, which includes optimal treatment selection using next-generation sequencing-based companion diagnostic systems and tumor-agnostic treatments according to common biom...

A diet-induced murine model for non-alcoholic fatty liver disease with obesity and insulin resistance that rapidly develops steatohepatitis and fibrosis.

Takafumi Sakuma Masato Nakamura Tetsuhiro Chiba Terunao Iwanaga Motoyasu Kan Ryuta Kojima Junjie Ao Yaojia Ma Hidemi Unozawa Naoto Fujita Kengo Kanayama Hiroaki Kanzaki Keisuke Koroki Kazufumi Kobayashi Ryo Nakagawa Naoya Kanogawa Soichiro Kiyono Takayuki Kondo Tomoko Saito Sadahisa Ogasawara Shingo Nakamoto Ryosuke Muroyama Jun Kato Takashi Kishimoto Naoya Kato

Laboratory investigation; a journal of technical methods and pathology 102(10) 1150-1157 2022年5月

Non-alcoholic fatty liver disease (NAFLD) has become the leading cause of chronic liver disease worldwide. Patients with NAFLD often suffer steatohepatitis, which can progress to cirrhosis and hepatocellular carcinoma. The presence of visceral obe...

Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trial.

Sadahisa Ogasawara Keisuke Koroki Hirokazu Makishima Masaru Wakatsuki Asahi Takahashi Sae Yumita Miyuki Nakagawa Takamasa Ishino Keita Ogawa Kisako Fujiwara Terunao Iwanaga Takafumi Sakuma Naoto Fujita Ryuta Kojima Hiroaki Kanzaki Kazufumi Kobayashi Soichiro Kiyono Masato Nakamura Naoya Kanogawa Tomoko Saito Takayuki Kondo Ryo Nakagawa Shingo Nakamoto Ryosuke Muroyama Tetsuhiro Chiba Yoshihito Ozawa Yohei Kawasaki Tomoya Kurokawa Hideki Hanaoka Hiroshi Tsuji Naoya Kato

BMJ open 12(4) e059779 2022年4月

INTRODUCTION: Advanced hepatocellular carcinoma (HCC) with macrovascular invasion (MVI) has the worst prognosis among all phenotypes. This trial aims to evaluate whether treatment with durvalumab, alone or in combination with tremelimumab, plus pa...